We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
PURITAN MEDICAL

BMG LABTECH

BMG LABTECH is a manufacturer of a wide range of dedicated and multi-mode microplate instruments ranging from single-... read more Featured Products: More products

Download Mobile App




Combination Urinary Biomarker Panel Detects Pancreatic Cancer Earlier

By LabMedica International staff writers
Posted on 11 Jan 2021
Print article
Image: The FLUOstar Omega Microplate Reader (Photo courtesy of BMG LABTECH).
Image: The FLUOstar Omega Microplate Reader (Photo courtesy of BMG LABTECH).
Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest cancers, with only around 9% of patients surviving more than 5 years. Asymptomatic in its initial stages, PDAC is mostly diagnosed late, when already a locally advanced or metastatic disease, as there are no useful biomarkers for detection in its early stages, when surgery can be curative.

While blood has traditionally been the main source of biomarkers, urine represents a promising alternative biological fluid. It allows a completely non-invasive sampling, high volume collection, and ease of repeated measurements; it has a lesser dynamic range, with a less complex proteome than blood.

Cancer specialist at the Queen Mary University of London (London, UK) and their colleagues obtained from multiple centers and a biomarker panel was assayed on 590 urine specimens: 183 control samples, 208 benign hepatobiliary disease samples (of which 119 were chronic pancreatitis), and 199 PDAC samples (102 stage I–II and 97 stage III–IV); 50.7% were from female individuals. PDAC samples were collected from patients before treatment. Blood and urine samples were analyzed with commercial enzyme-linked immunosorbent assay kits and the optical densities were determined using the FLUOstar Omega Microplate Reader (BMG LABTECH, Ortenberg, Germany).

The team changed their original protocol substituting Regenerating Family Member 1 Alpha (REG1A) with REG1B to enhance the performance of the panel to detect resectable PDAC. In a comparison of controls and PDAC stage I–II samples, the areas under the receiver operating characteristic curve (AUCs) increased from 0.900 and 0.926 in the training (50% of the dataset) and validation sets, respectively, to 0.936 in both the training and the validation (95% CI 0.888–0.984) datasets for the new panel including REG1B. This improved panel showed both sensitivity (SN) and specificity (SP) to be greater than 85%. Plasma CA19-9 enhanced the performance of this panel in discriminating PDAC I–II patients from controls, with AUC = 0.992, SN = 0.963, and SP = 0.967.

The authors concluded that they had successfully validated the performance of their urinary biomarker panel in detecting PDAC earlier. The PancRISK score is designed to enable further stratification of patients already predisposed to develop PDAC, thus enriching the population that should undergo follow-up, i.e., invasive clinical workup. The study was published on December 10, 2020 in the journal PLOS Medicine.





Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
HLX
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
New
Gold Member
Cancer Mutation Profiling Liquid Kit
OncoScreen Plus

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: The study showed the blood-based cancer screening test detects 83% of people with colorectal cancer with specificity of 90% (Photo courtesy of Guardant Health)

Blood Test Shows 83% Accuracy for Detecting Colorectal Cancer

Colorectal cancer is the second biggest cause of cancer deaths among adults in the U.S., with forecasts suggesting 53,010 people might die from it in 2024. While fewer older adults are dying from this... Read more

Hematology

view channel
Image: The Gazelle Hb Variant Test (Photo courtesy of Hemex Health)

First Affordable and Rapid Test for Beta Thalassemia Demonstrates 99% Diagnostic Accuracy

Hemoglobin disorders rank as some of the most prevalent monogenic diseases globally. Among various hemoglobin disorders, beta thalassemia, a hereditary blood disorder, affects about 1.5% of the world's... Read more

Microbiology

view channel
Image: The new platform is designed to perform blood-based diagnoses of nontuberculosis mycobacteria (Photo courtesy of 123RF)

New Blood Test Cuts Diagnosis Time for Nontuberculous Mycobacteria Infections from Months to Hours

Breathing in nontuberculous mycobacteria (NTM) is a common experience for many people. These bacteria are present in water systems, soil, and dust all over the world and usually don't cause any problems.... Read more

Industry

view channel
Image: These new assays are being developed for use on the recently introduced DxI 9000 Immunoassay Analyzer (Photo courtesy of Beckman Coulter)

Beckman Coulter and Fujirebio Expand Partnership on Neurodegenerative Disease Diagnostics

Beckman Coulter Diagnostics (Brea, CA, USA) and Fujirebio Diagnostics (Tokyo, Japan) have expanded their partnership focused on the development, manufacturing and clinical adoption of neurodegenerative... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.